Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The complaint claims that Lantheus misled investors about PYLARIFY's competitive position and failed to adequately assess pricing dynamics, which could jeopardize the product's revenue and growth potential [2]. - It is alleged that Lantheus did not disclose the implications of a price increase in early 2025, which followed a year of price erosion, potentially allowing for competitive pricing to undermine PYLARIFY's market position [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to apply to be appointed as lead plaintiffs, representing the class in the lawsuit [3]. - The lead plaintiff will select legal counsel to represent the class, and participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The lawsuit claims that Lantheus misled investors about PYLARIFY's competitive position, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's price point and revenue potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages Lantheus investors who have suffered losses to contact them for more information [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Insights - GE HealthCare (GEHC) has signed an exclusive license agreement with Lantheus Holdings to develop and commercialize the PSMA-targeted PET imaging agent, piflufolastat F18, in Japan for prostate cancer diagnostics [1][2]. Deal Overview - GEHC will develop, manufacture, and commercialize piflufolastat F18 in Japan, paying an upfront fee, milestone payments, and royalties on sales post-commercialization [2]. - Lantheus will provide regulatory dossiers, manufacturing competencies, and technical support to facilitate GEHC's clinical development efforts in Japan [2][11]. - The agent is already approved in the U.S. and Europe under the trade names PYLARIFY and PYLCLARI, respectively, for imaging in prostate cancer [3]. Market Potential - Japan has the third-largest number of prostate cancer cases globally, following the U.S. and China, making it a significant market for piflufolastat F18 [6]. - The aging population and increasing screening initiatives in Japan create a strong demand for advanced diagnostic solutions [6]. Strategic Implications - This agreement enhances GEHC's pipeline of radiopharmaceuticals and strengthens its Pharmaceutical Diagnostics division [9][10]. - The partnership validates GEHC's acquisition of Nihon Medi-Physics, which adds manufacturing and R&D capabilities essential for advancing prostate cancer detection [11]. Financial Performance - GEHC's shares have declined by 8.6% year-to-date, contrasting with a 4.7% gain in the industry and a 13.7% increase in the S&P 500 [4].

RADNOR, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered La ...

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the relevant period [2]. Group 2: Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

RADNOR, Pa., Sept. 12, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered La ...

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lantheus Holdings, Inc. due to allegations of providing misleading business information to investors [1]. Company Overview - Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care [3]. Alleged Wrongdoing - On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts [4]. - Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million, both below projections [4]. Market Reaction - Following the news of the disappointing results, Lantheus stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [5].

Sep 11, 2025 3:45 PM Eastern Daylight Time NASDAQ: LNTH: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Lantheus Holdings, Inc. Share RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus†) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26 ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Lantheus Holdings, Inc. for possible violations of federal securities laws and unlawful business practices following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On August 6, 2025, Lantheus reported second quarter 2025 results with earnings-per-share (EPS) and revenue figures that missed market expectations [3]. - The company lowered its full year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion, and adjusted fully diluted EPS guidance from $6.60 - $6.70 per share to $5.50 - $5.70 per share [3]. - Consolidated net revenue for the second quarter was $378 million, a decrease of 4.1%, with sales from the radiopharmaceutical oncology product PYLARIFY contributing $250.6 million, down 8.3% [3]. Stock Market Reaction - Following the announcement of the disappointing results, Lantheus's stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [3].